logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

April 2020 Update to The Canadian Reimbursement Trends & Timelines Report – Now Available

April 27, 2020
-
Market Access News, Publications, What's New
-
Posted by MORSE - < 1 min read.

Toronto, April 27, 2020 – MORSE Consulting is pleased to release our April 2020 Update to the Canadian Reimbursement Trends and Timelines report – a comprehensive, credible and relevant source of market access intelligence.

This 50+ PowerPoint report is aimed at assisting market access professionals plan for future launches and also serves as a valuable education tool for both internal and external stakeholders.

What’s New in the April 2020 Update?

  • Full coverage of the 2019 pCPA Calendar Year as well as comparisons with previous years.
  • Jurisdictional funding update of 2018 completed negotiations & 2019 completed negotiations, complete with metrics stratified by oncology & non-oncology subtypes.
  • Market Access Timelines from CADTH Submission to public listing in each jurisdiction, stratified by oncology & non-oncology.

Please click here to learn more about our new report.

 

About the Authors: 

MORSE Consulting Inc. is a leader in strategic pharmaceutical market access consulting in Canada. Our team has significant expertise in reimbursement strategy in a wide range of therapeutic areas and has built a reputation for providing meaningful strategic insights. MORSE has established strong, constructive relationships with healthcare stakeholders and a proven track record for delivering impactful results to its clients. 

Share
Tags
CADTH
CDR
HTA
INESSS
Market Access Strategy
pCODR
pCPA
pCPAO
Public Payers
Reimbursement strategy
TTL
← PREVIOUS POST
Summary of CADTH Pharmaceutical Reviews Update - Issue 15
NEXT POST →
New pCPA Website & Available Data

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
April 2020 Update to The Canadian Reimbursement Trends & Timelines Report - Now Available